Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.29% | -50.22% | -21.33% | -25.26% | -28.28% |
| Depreciation & Amortization | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.98% | -87.44% | -21.97% | -27.54% | -28.33% |
| Operating Income | 26.98% | 87.43% | 20.13% | 21.91% | 28.09% |
| Income Before Tax | 49.54% | -158.95% | -1.33% | 42.18% | -72.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.54% | -158.95% | -1.33% | 42.18% | -72.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.54% | -158.95% | -1.33% | 42.18% | -72.77% |
| EBIT | 26.98% | 87.43% | 20.13% | 21.91% | 28.09% |
| EBITDA | -- | 87.53% | 20.27% | 22.06% | 28.28% |
| EPS Basic | 53.85% | -157.89% | 0.00% | 45.45% | -85.71% |
| Normalized Basic EPS | 50.00% | 76.00% | 0.00% | 42.86% | -60.00% |
| EPS Diluted | 53.85% | -157.89% | 0.00% | 45.45% | -85.71% |
| Normalized Diluted EPS | 50.00% | 76.00% | 0.00% | 42.86% | -60.00% |
| Average Basic Shares Outstanding | 3.38% | 2.15% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 3.38% | 2.15% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |